Naltrexone does not block nicotine directly. It blocks opioid receptors in the brain, not nicotine receptors. However, because smoking triggers the release of your body’s natural opioids (endorphins), naltrexone can dampen some of the pleasure and reward you get from cigarettes. This indirect effect has made it a subject of interest for smoking cessation research, though the results are mixed and it is not FDA-approved for nicotine addiction.
How Naltrexone Affects the Smoking Experience
When you smoke a cigarette, nicotine binds to receptors in your brain and triggers a cascade of feel-good chemicals, including endorphins. Naltrexone works by blocking the receptors where those endorphins land. It doesn’t stop nicotine from reaching your brain or prevent the initial nicotine hit. Instead, it intercepts part of the reward signal downstream, making the overall experience less satisfying.
Clinical trials confirm this effect. In a randomized controlled trial published in the journal Addiction, smokers taking naltrexone before their quit date reported lower cigarette pleasure, reduced taste enjoyment, and less urge to smoke compared to those on a placebo. The differences were modest but statistically significant. In practical terms, people on naltrexone described cigarettes as less appealing, not as something they suddenly had no desire for.
What the Quit Rate Data Shows
The picture gets complicated when you look at whether naltrexone actually helps people stop smoking for good. In a 12-week trial of 315 smokers, naltrexone improved quit rates during active treatment and delayed the time to first cigarette (21 days on naltrexone versus about 15 days on placebo). Smoking urge scores dropped more sharply in the naltrexone group as well. Men saw the clearest benefit: 30% quit rates on naltrexone compared to 17% on placebo, and men on naltrexone smoked roughly 32 cigarettes per week versus about 50 for those on placebo.
Women in the same trial, however, did not benefit. Their quit rates were actually slightly lower on naltrexone (20%) than on placebo (28%), and their weekly cigarette counts were nearly identical between groups. Researchers still don’t fully understand why this sex difference exists, but it has appeared consistently enough to raise questions about whether naltrexone for smoking works differently depending on biological sex.
Long-term results are also discouraging. By 26 weeks after treatment ended, quit rates were identical at 26% in both groups. By one year, the naltrexone group had a lower quit rate (17%) than placebo (23%). Whatever short-term advantage naltrexone provided during active treatment did not persist once people stopped taking it.
Higher Doses and Nicotine Patches
A large trial of 400 heavy smokers (averaging about 27 cigarettes per day) tested naltrexone at three different doses alongside nicotine patches. In the full group of participants, none of the naltrexone doses significantly outperformed placebo for sustained abstinence. Among those who completed the full course of treatment, though, the highest dose (100 mg daily) stood out: 71.6% achieved continuous abstinence compared to 48% on placebo. This suggests that higher doses may be more effective, but only for people who can tolerate the medication and stick with it through the full treatment period. Doses of 25 mg and 50 mg did not show meaningful advantages.
Why Adding Naltrexone to Other Quit Medications Backfires
You might assume that combining naltrexone with a proven quit-smoking medication would improve results. A clinical trial tested exactly this by pairing naltrexone with varenicline (the active ingredient in Chantix) in heavy-drinking smokers. The results were the opposite of what researchers expected. Varenicline alone produced a 45% quit rate at six months. Adding naltrexone dropped that to about 25%. The combination was significantly worse than varenicline by itself.
The researchers described this as an “iatrogenic effect,” meaning the added medication actually caused harm to outcomes. The likely explanation involves how these drugs interact with overlapping brain reward systems. Varenicline partially activates the same nicotine receptors that cigarettes target, providing a mild substitute effect that eases cravings. Naltrexone may interfere with that substitute signal by dampening the opioid component of the reward. The takeaway is clear: if you’re already on a standard quit-smoking medication, adding naltrexone is not likely to help and could make things harder.
Not Approved for Smoking Cessation
Naltrexone is FDA-approved for alcohol use disorder (in both pill and injectable forms) and opioid use disorder (injectable form only). It has no FDA approval for nicotine addiction or smoking cessation in any form. Any use for quitting smoking is off-label, and the mixed clinical evidence explains why regulators haven’t moved forward with approval. The short-term benefits in some subgroups, particularly men, haven’t translated into the kind of consistent, durable results that would support a new indication.
The Sex Difference Problem
One of the most striking findings across naltrexone smoking trials is how differently men and women respond. In men, naltrexone nearly doubled quit rates and cut weekly cigarette consumption by more than a third during treatment. In women, it had essentially no effect on either measure. This pattern makes it difficult to recommend naltrexone broadly for smoking cessation, even off-label. Some researchers have suggested that hormonal differences in the opioid system may explain the gap, but this remains an open question. If you’re a man exploring options for quitting, naltrexone might be worth discussing with a prescriber as an add-on to nicotine replacement. For women, the existing evidence doesn’t support the same rationale.
What This Means for Vaping
Nearly all of the clinical research on naltrexone and nicotine involves traditional cigarettes. No major trials have tested naltrexone specifically for e-cigarette or vaping cessation. Since the underlying pharmacology is the same (nicotine triggering endorphin release, naltrexone blocking the opioid component), there’s a theoretical basis for a similar effect. But vaping delivers nicotine in different concentrations and patterns than cigarettes, and the behavioral habits are distinct. Without direct evidence, it’s not possible to say whether the modest benefits seen in some smoking trials would carry over to people trying to quit vaping.